EHNAC - Electronic Healthcare Network Accreditation Commission competitors

Mike McMullen is Agilent’s CEO-elect. He will assume the CEO position in March 2015 when William (Bill) Sullivan takes an advisory role until his retirement. As a first step in the CEO transition, McMullen has been named president and chief operating officer. McMullen has more than 30 years of industry experience and senior management experience at Agilent. He has been president of the company’s Chemical Analysis Group (CAG) since 2009, a role he still fills on an acting basis. As head of CAG, McMullen transformed the business, consistently delivering market-leading growth and profits. He championed strategic acquisitions and architected Agilent’s China strategy. He built the Agilent-wide Services business that has now been made one of Agilent’s three major businesses. McMullen has extensive experience working across Agilent’s businesses, and is recognized for his inspirational leadership style. He also has significant international experience, having lived in Japan, leading Agilent’s Japan field sales and support operations, and later adding responsibility for China field operations. McMullen joined Agilent’s predecessor, Hewlett-Packard Co., in 1984 as a financial analyst. He holds a bachelor's degree in economics and business administration from the University of Delaware and an MBA from Wharton Business School.

Mr. Michael Klein serves as the Chairman and CEO for iCAD Medical (Nasdaq: ICAD), a clinical artificial intelligence company focused on the detection of breast cancer and other proliferative diseases. iCAD's, therapy subsidiary, Xoft Inc. uses novel electronic brachytherapy for the treatment of breast and gynecological cancers as well as brain, rectal and prostate cancers. Between December 2014 and October 2018, when he assumed the above position, Mr. Klein served as Chief Executive Officer at Inflection Point Consulting, an executive coaching and consulting firm with a focus on medical technology, biopharma and healthcare services. During this same time period, Mr. Klein served as a Adjunct Professor at the Leavey School of Business at Santa Clara University. Prior to that, from December 2011 to November 2014. Klein was the Chief Executive Officer at SonaCare Medical, LLC (f/k/a US HIFU, LLC), a global leader in minimally invasive high intensity focused ultrasound technologies used for the treatment of prostate and other urological cancers. From April 2011 to December 2011, Mr. Klein was the President of the Civco Radiation Oncology Division within Roper Industries, a diversified industrial company that produces engineered products for global niche markets. He was President and Chief Executive Officer of Xoft, Inc., a medical device company, a position he held from December 2004 until the sale of Xoft to iCAD Medical in December 2010. Prior to joining Xoft, from 2000 to 2004, Mr. Klein served as Chairman, President and Chief Executive Officer of R2 Technology, Inc., a breast and lung cancer computer aided detection company. The first company to bring a medical artificial intelligence technology before the FDA and receive PMA Regulatory Approval. Previously, Mr. Klein served in VP, Sales and Marketing roles at Varian Medical Systems (VAR) and Becton Dickinson (BDX). Mr. Klein received a Bachelor of Arts degree from the University at Albany, SUNY. Mr. Klein also received his M.B.A. from the New York Institute of Technology and completed his post-graduate Executive Education Studies at Harvard University and Babson College. Mr. Klein lives in Mountain View, California with his wife and 3 children, in close proximity. Mr. Klein splits time between iCAD headquarters in Nashau, NH and Xoft’s headquarters in San Jose, CA.

Joined Varian as an intern in 1999, then full time in 2001, and has held multiple cross-functional roles and executive positions during two-decade tenure with the company. Intimate understanding of healthcare, software solutions, medical devices, technology trends, reimbursement trends and strategies that lead to success in targeted channel segments globally. Marketing strategy, new product launch, portfolio strategy, M&A, P&L, restructuring, government relations, and general management experience. Consistent creation of strategies and execution against operating plans, sales goals and market objectives, including extensive experience of both high growth and slow growth periods (turnaround plans) of Varian Medical Systems journey from $500M to over $3B. Including returning Varian to double digit growth following becoming President of the $3B+ P&L of Oncology systems. Strong leadership skills with a track record of creating an inspiring vision and communicating effectively both internally/externally through developing cultural, servant leadership and focusing on people/teams to drive net promoter scores to all-time highs and enable sustainable long-term success.

Ms. Mary C. Starmann-Harrison is a President and Chief Executive Officer at Hospital Sisters Health System and is based in United States.